Photocure set for 2012 completion of Phase II Cevira trial for cervical HPV
This article was originally published in Scrip
Norway's Photocure is preparing the ground to progress its photodynamic therapy for cervical human papilloma virus (HPV) infection, Cevira, into Phase III having begun enrolment into a Phase II trial evaluating the optimal dose and safety of the product. "The study is designed to be the study that will form the platform for the final Phase III program of Cevira, and the results of the [Phase II] trial are anticipated in the second half 2012," the company said.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.